AstraZeneca Results Presentation Deck
Pipeline catalysts for 2021 2022
Industry leading news flow
35
|N
Regulatory
decision
Regulatory
submission
and/or
acceptance
Key Phase III
data readouts
Oncology BioPharmaceuticals Rare Disease
Q4 2021
AZD7442-COVID-19 prophylaxis (US)
-
Imfinzi + tremelimumab - NSCLC (1L) (POSEIDON)
Lynparza - breast cancer (adjuvant)
Lynparza - mCRPC (1L)
Enhertu - breast cancer (2L, HER2+)
AZD7442-COVID-19 prophylaxis (EU CMA, JP)
AZD7442-COVID-19 outpatient treatment (US EUA)
Ultomiris - subcutaneous formulation in PNH and aHUS
Ultomiris - generalised myasthenia gravis
AZD2816-COVID-19 (variants of concern)
H1 2022
Brilique - stroke (THALES) (EU, CN)
Forxiga - chronic kidney disease (CN)
Fasenra - nasal polyps (US)
Saphnelo - lupus (SLE) (EU)
tezepelumab - asthma (US, EU, JP)
Imfinzi +/- tremelimumab - liver cancer (1L)
Imfinzi - biliary tract cancer (TOPAZ-1)
Enhertu - HER2-low breast cancer (DESTINY-Breast04)
Calquence - CLL (ELEVATE-TN) (JP)
Koselugo - NF1 (JP, CN)
Farxiga - HF (HFpEF)
PT027 - asthma (US)
Vaxzevria - COVID-19 (US)
nirsevimab - respiratory syncytial virus
Imfinzi - NSCLC (1L) (PEARL)
Imfinzi - cervical cancer (CALLA)
Imfinzi - unresectable, Stage III NSCLC (PACIFIC-2)
Enhertu - HER2-low breast cancer (DESTINY-Breast04)
Farxiga - HFPEF (DELIVER)
Ultomiris - neuromyelitis optica spectrum disorder
H2 2022
Tagrisso - EGFRm NSCLC (adjuvant) (JP)
Enhertu - gastric cancer (2L+, HER2+) (EU)
Imfinzi - unresectable, Stage III NSCLC (PACIFIC-2)
Imfinzi - NSCLC (1L) (PEARL)
Imfinzi - cervical cancer (CALLA)
Imfinzi - locoregional liver cancer (EMERALD-1)
Enhertu - HER2+ breast cancer (3L) (DESTINY-Breast02)
Fasenra- eosinophilic oesophagitis (MESSINA)
Ultomiris - neuromyelitis optica spectrum disorder
ALXN1840 - Wilson disease
acoramidis transthyretin amyloid cardiomyopathy
Imfinzi - limited-stage SCLC (ADRIATIC)
Imfinzi - liver cancer (locoregional) (EMERALD-1)
Enhertu - HER2+ breast cancer (3L) (DESTINY-Breast02)
Fasenra - hyper-eosinophilic syndrome (NATRON)
Fasenra- eosinophilic oesophagitis (MESSINA)
Fasenra - chronic spontaneous urticaria (ARROYO)
Fasenra - atopic dermatitis (HILLIER)
danicopan - PNH with extravascular haemolysis
acoramidis - transthyretin amyloid cardiomyopathyView entire presentation